GRIFOLS SHARED SERVICES NORTH AMERICA, INC. for GRIFOLS SHARED SERVICES NORTH AMERICA INC
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Tariff (miscellaneous tariff bills) TAR
Issues related to tariff policy; tariffs on pharmaceuticals and related products
Foreign entity interest: Issues related to the delivery of plasma-derived therapies
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROSEMARY GARZA | — |
| CHRISTOPHER HEALEY | — |
| KATHERINE PAJEWSKI | — |
| MICHAEL PIERSALL | — |
Health Issues HCR
H.R. 1476 / S. 694 Preserving Life-Saving Access to Specialty Medicines in America Act (PLASMA Act);Phases in manufacturer discounts for plasma‑derived therapies under the Medicare Part D Manufacturer Discount Program, gradually increasing required discounts over several years to avoid sudden cost impacts on access to plasma‑derived medicines. H.R. 1143 Medicare IVIG Access Enhancement Act of 2025;Expands Medicare coverage for in‑home administration of intravenous immune globulin (IVIG) to include treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy, in addition to primary immune deficiency diseases. H.R. 2343 John W. Walsh Alpha‑1 Home Infusion Act of 2025;Provides Medicare coverage for at‑home augmentation therapy for beneficiaries with emphysema resulting from severe hereditary alpha‑1 antitrypsin (AAT) deficiency when furnished by qualified home infusion therapy suppliers. S. 1818 / H.R. 3546 Prescription Drug Price Relief Act of 2025;Requires HHS to annually review brand‑name drugs for excessive pricing and, when prices exceed specified international benchmarks or reasonableness standards, to void government‑granted exclusivities and facilitate generic or biosimilar competition. S. 1587 / H.R. 3375 Fair Prescription Drug Prices for Americans Act;Establishes an international reference pricing system that caps U.S. retail list prices for certain prescription drugs and biologics at the average price in selected peer countries, with penalties for manufacturers that exceed the cap. S. 1753 End Price Gouging for Medications Act;Requires HHS to set annual reference prices for prescription drugs, generally based on the lowest prices in selected foreign markets, and prohibits retail prices under federal health programs from exceeding those reference prices. Issues related to Most Favored Nations drug pricing proposals (incl. H.R. 7837) Most Favored Patient Act of 2026; Directs the Center for Medicare and Medicaid Innovation to test a model implementing most‑favored‑nation drug pricing, tying Medicare payment rates to lower prices paid in comparable foreign countries. Issues related to the implementation of P.L. 117-169, the Inflation Reduction Act; drug price negotiations, Part D rebate Issues related to the 340B program
Foreign entity interest: Issues related to the delivery of plasma-derived therapies.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROSEMARY GARZA | — |
| CHRISTOPHER HEALEY | — |
| KATHERINE PAJEWSKI | — |
| MICHAEL PIERSALL | — |
Budget/Appropriations BUD
FY2026 Appropriations bill for Labor, Health and Human Services
Foreign entity interest: Issues related to the delivery of plasma-derived therapies
| Lobbyist | Covered position, as disclosed |
|---|---|
| ROSEMARY GARZA | — |
| CHRISTOPHER HEALEY | — |
| KATHERINE PAJEWSKI | — |
| MICHAEL PIERSALL | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.